To include your compound in the COVID-19 Resource Center, submit it here.

VBI's CMV vaccine induces 100% seroconversion in Phase I

VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV) reported interim data from a single-blind, Canadian Phase I trial in 128

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE